lilly retatrutide trial Lilly's triple agonist achieves 16.8% weight loss in phase 3 eli lilly retatrutide trial sign

And if you're on no GLP-1 yet and you're trying to decide where to start, the answer depends entirely on your individual physiology

The 16.8% weight loss in this population is substantially below TRIUMPH-1's 28.3% a pattern consistent across the GLP-1 drug class, where type 2 diabetes reduces the magnitude of weight loss compared to non-diabetic obesity populations

PRICE AND COST SHARING INFORMATION FOR ENROLLEES New federal rules will require health plans (including self-funded plans) to make information available to enrollees about the estimated cost of services and cost-sharing on a real-time basis

23 These symptoms can be severe in some patients, resulting in a pause of dose escalation, and if intolerable GI symptoms continue, a dose adjustment to the previous lower dose or a switch to an alternative GLP-1 RA should be considered

I sourced through a Canadian supplier (third-party tested, ships from BC) and kept it simple